This content is machine translated Hodgkin's lymphoma No more transplants for relapsed or refractory HL in the future? The standard treatment approach for relapsed or refractory (RR) classical Hodgkin’s lymphoma (HL) after failure of first-line treatment is second-line therapy with the aim of achieving complete remission (CR), followed...…
View Post 4 min This content is machine translated Cutaneous squamous cell carcinoma A dermato-oncological challenge in advanced stages The treatment options for locally advanced and metastatic forms of cutaneous squamous cell carcinoma (cSCC) have improved considerably thanks to immunotherapy with PD-1 inhibitors, as several clinical studies have impressively…
View Post 2 min This content is machine translated Breast Cancer Regulatory extension for anti-PD-1 therapy with pembrolizumab Swissmedic has granted a further marketing authorization for anti-PD-1 therapy with pembrolizumab. This can now be approved in combination with chemotherapy in Switzerland for the treatment of patients with locally…
View Post 1 min This content is machine translated Squamous cell carcinoma Pembrolizumab as first-line therapy reduces mortality rate In a phase III trial, pembrolizumab improved overall survival in patients with recurrent or metastatic head and neck squamous cell carcinoma.
View Post 4 min This content is machine translated 28th German Skin Cancer Congress 2018, Stuttgart Update on immunotherapy of malignant melanoma Combination immunotherapy, adjuvant immune checkpoint blockade, and long-term survival after PD-1 inhibitor therapy were the topics of two satellite symposia at the German Skin Cancer Congress.
View Post 11 min This content is machine translated ASCO 2018 in Chicago Study news on lung, kidney and intestine KEYNOTE-042 and CARMENA: Two studies that have the potential to change practice. It’s about lung cancer – as so often lately – but also about renal cell carcinoma. Furthermore, the…
View Post 5 min This content is machine translated ESMO in Copenhagen and Singapore Immunotherapy puts lung cancer experts in turmoil Pembrolizumab returned to the international stage of lung cancer therapy with a thunderclap during the presentation of the KEYNOTE 024 trial at the 2016 ESMO Congress in Copenhagen. Lectures on…
View Post 3 min This content is machine translated Advanced melanoma Pembrolizumab is superior to ipilimumab There is news on the KEYNOTE-006 study evaluating pembrolizumab (Keytruda®) for the treatment of advanced melanoma. The study was terminated early after the defined endpoints consisting of progression-free and overall…
